Product
Narsoplimab
Aliases
Biological: narsoplimab
1 clinical trial
2 indications
Indication
Thrombotic MicroangiopathyIndication
Hematopoietic Stem Cell TransplantationClinical trial
A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic MicroangiopathyStatus: Recruiting, Estimated PCD: 2025-12-01